Palleon Pharmaceuticals and Shanghai Henlius Biotech have entered a licence agreement and partnership for the former’s ...

Shanghai Henlius Biotech, Inc. Class H (HK:2696) has released an update.Don't Miss Our Christmas Offers:Discover the latest stocks recommended ...

Shanghai Henlius Biotech, Inc. Class H (HK:2696) has released an update. Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter ...

Shanghai Henlius Biotech, Inc. Class H (HK:2696) has released an update. Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter ...

Overview: Shanghai Henlius Biotech, Inc. focuses on the research and development of biologic medicines targeting oncology, autoimmune diseases, and ophthalmic diseases, with a market cap of HK$12. ...

Palleon Pharmaceuticals, a company pioneering glyco-immunology drug development to treat autoimmune diseases and cancer, today announced a collaboration and license agreement with Shanghai Henlius ...

As global markets experience fluctuations with major indexes like the Nasdaq Composite reaching new highs, small-cap stocks face challenges as evidenced by the Russell 2000's recent underperformance.

today announced a collaboration and license agreement with Shanghai Henlius Biotech, Inc. (2696.HK) to develop and commercialize Palleon’s first-in-class human sialidase enzyme therapeutic ...